The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G04 | Urologicals | |
| 3 | G04B | Other urologicals, incl. antispasmodics | |
| 4 | G04BE | Drugs used in erectile dysfunction | |
| 5 | G04BE08 | Tadalafil |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Tadalafil |
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CIALIS 2.5 mg Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CIALIS 5 mg Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| QUATOR Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| TADALAFIL MYLAN Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TALMANCO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TRIPAN 20mg Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| TRIPAN 5mg Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
